EGFR and non-small cell lung carcinoma: Based on our viability data with GZ17-6.02 and pemetrexed in ERBB1 inhibitor-resistant NSCLC cells, we compared and contrasted the ability of the drug combination to alter signaling and protein expression in H1975 cells; wild-type sensitive; afatinib-resistant; and osimertinib-resistant.